Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Biogen scraps late-stage trials for Alzheimer’s drug

Biogen Inc. and Eisai Co. Ltd. are abandoning two late-stage trials for their Alzheimer’s treatment elenbecestat in a widely anticipated move that comes months after the companies scrapped studies of aducanumab for the memory-robbing disease.

Read More »

Acadia Halts Psychosis Clinical Trial Early for Nuplazid

Shares of Acadia Pharmaceuticals were up nearly 70 percent after a Phase III psychosis trial was halted early as the Parkinson’s disease drug Nuplazid hit primary endpoints, positioning the company to seek another potential regulatory approval.

Read More »

NJ ice cream shop teams up with ALS Ice Bucket Challenge co-founder

Seven Scoops ice cream shop in Pine Brook, New Jersey, is donating every penny of ice cream sales on Aug. 26th to support ALS Ice Bucket Challenge Co-Founder Pat Quinn.

Read More »

Multiple sclerosis drug helps Biogen beat Wall St. profit expectations

Biogen Inc. reported better-than-expected second quarter 2019 profit and raised the company’s full-year earnings forecast, driven by higher sales of the top-selling multiple sclerosis drug Tecfidera and lower taxes.

Read More »

Biohaven’s ALS treatment fails to win FDA nod

Biohaven Pharmaceutical Holding Co. Ltd. said the U.S. health regulator failed to approve the company’s treatment for amyotrophic lateral sclerosis, or Lou Gehrig’s disease.

Read More »

Novartis’ SMA Gene Therapy Treatment Approved by FDA, Priced at $2.125 Million

The U.S. Food and Drug Administration approved Zolgensma, a gene therapy that Novartis called a life-changing medicine, for children younger than 2 years of age who have been diagnosed with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 gene.

Read More »

Cytokinetics’ ALS Treatment Fails to Hit Endpoints in Phase II, Company Notes Several Positive Results

Shares of Cytokinetics Inc. were down more than 15 percent after the company announced that the experimental amyotrophic lateral sclerosis treatment reldesemtiv failed to hit endpoints in a Phase II trial.

Read More »

Neurocrine’s Opicapone Plus Levodopa Improves Parkinson’s Symptoms

San Diego-based Neurocrine Biosciences presented data from two Phase III clinical trials of opicapone, a once-daily, oral catechol-O-methyltransferase (COMT) inhibitor for Parkinson’s disease.

Read More »

The obscure advisory committees at the heart of the U.S. drug pricing debate

Expectations were high during 2018 for three new migraine drugs hitting the market from Amgen Inc., Eli Lilly and Co. and Teva Pharmaceutical Industries Ltd. Priced around $7,000 each, the drugmakers called them “breakthrough” treatments designed to prevent migraines when taken year-round, and estimated that millions of patients could benefit. But a small group of medical experts who quietly advise U.S. health insurers on new drugs was not impressed, according to a private meeting held at UnitedHealth Group’s OptumRx offices in Chicago that was attended by Reuters.

Read More »

Novartis MS drug wins FDA’s blessing amid scrutiny of $88k annual price

Novartis AG won U.S. Food and Drug Administration approval for the multiple sclerosis drug Mayzent as the Swiss company targets patients whose disease advances from intermittent attacks to a gradually worsening condition.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom